Loading
Life sciences · Journal article
Journal of Nanobiotechnology · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Oncolytic virus therapy, as an emerging anti-tumor biological therapy, has demonstrated significant therapeutic potential for brain tumors in clinical studies. However, due to the special anatomical barrier of the brain tissue, the application of oncolytic viruses is currently limited to the intracranial administration route, which restricts its clinical convenience and safety. Herein, we propose a biomimetic composite strategy, utilizing the characteristic of Escherichia coli K1 (EC-K1) that can efficiently enter the brain through the nasal-brain pathway, and modifying its outer membrane vesicles (OMVs) on the surface of oncolytic adenovirus serotype 11 (Ad11@dOMV). The results show that the efficiency of Ad11@dOMV crossing the nasal-brain barrier after nasal administration in vivo is about 581 times higher than that of the unmodified virus, and it achieves comparable anti-tumor efficacy to intracranial administration in the lung cancer brain metastasis model. This strategy provides a feasible path for non-invasive nasal delivery of oncolytic viruses.